Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Nanoplatforms Based Cancers Therapy 2.0
share announcement

Nanoplatforms Based Cancers Therapy 2.0

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 7733

Special Issue Editor

Dr. Magali Gary-Bobo

E-Mail Website
Guest Editor
IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France
Interests: photodynamic therapy; two-photon excitation; cancer targeting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the previous release, “Nanoplatforms Based Cancers Therapy” (https://www.mdpi.com/journal/cancers/special_issues/Nanoplatforms_Cancers).

Nanomedicine is now considered a hopeful strategy with which to efficiently target cancer cells and deliver, more specifically, the molecule of interest to the area to imaging and treatment. A large variety of biocompatible nanoparticles have been produced in the last few years to carry and protect from biological barriers those molecules that are designed for imaging or therapy. In addition, grafting with targeting moieties allows the tumor area to be better addressed. Finally, a stimuli response system such as laser, temperature or ultrasounds to deliver the cargo to the selected site, can add a supplementary dimension to the conception of high-potency controlled nanodevices.

In this Special Issue, we will focus on novel nanoplatforms for the therapy and/or imaging of cancers. The therapeutic strategy could be drug or nucleic acid delivery, or photodynamic, photothermal or ultrasounds therapy; in addition, surface ligands anchoring could be a strong advantage to efficiently introduce the nanoplatforms to the tumor area and, more particularly, to cancer cells. This Special Issue aims to highlight novel nanodevices with cancer applications.

Dr. Magali Gary-Bobo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoplatforms
  • cancer therapy
  • imaging
  • targeting
  • controlled delivery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 4640 KiB  
Article
Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models
by Esperanza Medina-Gutiérrez, Annabel García-León, Alberto Gallardo, Patricia Álamo, Lorena Alba-Castellón, Ugutz Unzueta, Antonio Villaverde, Esther Vázquez, Isolda Casanova and Ramon Mangues
Cancers 2023, 15(1), 85; https://doi.org/10.3390/cancers15010085 - 23 Dec 2022
Cited by 2 | Viewed by 1742
Abstract
Patients with advanced endometrial cancer (EC) show poor outcomes. Thus, the development of new therapeutic approaches to prevent metastasis development in high-risk patients is an unmet need. CXCR4 is overexpressed in EC tumor tissue, epitomizing an unexploited therapeutic target for this malignancy. The [...] Read more.
Patients with advanced endometrial cancer (EC) show poor outcomes. Thus, the development of new therapeutic approaches to prevent metastasis development in high-risk patients is an unmet need. CXCR4 is overexpressed in EC tumor tissue, epitomizing an unexploited therapeutic target for this malignancy. The in vitro antitumor activity of two CXCR4-targeted nanoparticles, including either the C. diphtheriae (T22-DITOX-H6) or P. aeruginosa (T22-PE24-H6) toxin, was evaluated using viability assays. Apoptotic activation was assessed by DAPI and caspase-3 and PARP cleavage in cell blocks. Both nanotoxins were repeatedly administrated to a subcutaneous EC mouse model, whereas T22-DITOX-H6 was also used in a highly metastatic EC orthotopic model. Tumor burden was assessed through bioluminescence, while metastatic foci and toxicity were studied using histological or immunohistochemical analysis. We found that both nanotoxins exerted a potent antitumor effect both in vitro and in vivo via apoptosis and extended the survival of nanotoxin-treated mice without inducing any off-target toxicity. Repeated T22-DITOX-H6 administration in the metastatic model induced a dramatic reduction in tumor burden while significantly blocking peritoneal, lung and liver metastasis without systemic toxicity. Both nanotoxins, but especially T22-DITOX-H6, represent a promising therapeutic alternative for EC patients that have a dismal prognosis and lack effective therapies. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 2371 KiB  
Review
Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors
by Rebecca Leah Benhaghnazar and Lali Medina-Kauwe
Cancers 2023, 15(12), 3240; https://doi.org/10.3390/cancers15123240 - 19 Jun 2023
Viewed by 1579
Abstract
Macromolecular therapeutics such as nucleic acids, peptides, and proteins have the potential to overcome treatment barriers for cancer. For example, nucleic acid or peptide biologics may offer an alternative strategy for attacking otherwise undruggable therapeutic targets such as transcription factors and similar oncologic [...] Read more.
Macromolecular therapeutics such as nucleic acids, peptides, and proteins have the potential to overcome treatment barriers for cancer. For example, nucleic acid or peptide biologics may offer an alternative strategy for attacking otherwise undruggable therapeutic targets such as transcription factors and similar oncologic drivers. Delivery of biological therapeutics into tumor cells requires a robust system of cell penetration to access therapeutic targets within the cell interior. A highly effective means of accomplishing this may be borrowed from cell-penetrating pathogens such as viruses. In particular, the cell entry function of the adenovirus penton base capsid protein has been effective at penetrating tumor cells for the intracellular deposition of macromolecular therapies and membrane-impermeable drugs. Here, we provide an overview describing the evolution of tumor-targeted penton-base-derived nano-capsids as a framework for discussing the requirements for overcoming key barriers to macromolecular delivery. The development and pre-clinical testing of these proteins for therapeutic delivery has begun to also uncover the elusive mechanism underlying the membrane-penetrating function of the penton base. An understanding of this mechanism may unlock the potential for macromolecular therapeutics to be effectively delivered into cancer cells and to provide a treatment option for tumors resisting current clinical therapies. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy 2.0)
►▼ Show Figures

Graphical abstract

58 pages, 2391 KiB  
Review
DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors
by Anastasiya N. Shishparenok, Vitalina V. Furman and Dmitry D. Zhdanov
Cancers 2023, 15(7), 2151; https://doi.org/10.3390/cancers15072151 - 05 Apr 2023
Cited by 5 | Viewed by 3805
Abstract
DNA nanotechnology has significantly advanced and might be used in biomedical applications, drug delivery, and cancer treatment during the past few decades. DNA nanomaterials are widely used in biomedical research involving biosensing, bioimaging, and drug delivery since they are remarkably addressable and biocompatible. [...] Read more.
DNA nanotechnology has significantly advanced and might be used in biomedical applications, drug delivery, and cancer treatment during the past few decades. DNA nanomaterials are widely used in biomedical research involving biosensing, bioimaging, and drug delivery since they are remarkably addressable and biocompatible. Gradually, modified nucleic acids have begun to be employed to construct multifunctional DNA nanostructures with a variety of architectural designs. Aptamers are single-stranded nucleic acids (both DNAs and RNAs) capable of self-pairing to acquire secondary structure and of specifically binding with the target. Diagnosis and tumor therapy are prospective fields in which aptamers can be applied. Many DNA nanomaterials with three-dimensional structures have been studied as drug delivery systems for different anticancer medications or gene therapy agents. Different chemical alterations can be employed to construct a wide range of modified DNA nanostructures. Chemically altered DNA-based nanomaterials are useful for drug delivery because of their improved stability and inclusion of functional groups. In this work, the most common oligonucleotide nanomaterials were reviewed as modern drug delivery systems in tumor cells. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy 2.0)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop